Medical Marijuana, Inc. v. Horn
Case Overview
Douglas Horn, a truck driver, used a CBD product marketed as THC-free by Medical Marijuana, Inc. and subsequently failed a drug test, losing his commercial driver's license. The Supreme Court held 5-4 that the Controlled Substances Act's civil remedies provision does not categorically bar a RICO claim by a plaintiff whose injury was proximately caused by fraud, even where a controlled substance was part of the causal chain.
The Facts
Horn purchased Dixie X, a CBD oil the company marketed as containing no THC, to manage chronic pain. The product contained THC. Horn failed a mandatory drug test and was terminated, losing his commercial driver's license and his livelihood. He sued under RICO, alleging a pattern of racketeering through fraudulent marketing. The Second Circuit dismissed, holding the CSA's civil remedies provision barred claims by persons injured by reason of a controlled substance.
The Application
Under this rule, Horn's injury was proximately caused by Medical Marijuana, Inc.'s fraudulent marketing—specifically the false representation that Dixie X contained no THC—rather than by the controlled substance violation itself. Although THC was present in the product's causal chain leading to his failed drug test and job loss, the Court found that the relevant proximate cause was the company's deceptive labeling, which induced Horn's reliance and set the harmful sequence in motion. By establishing this fraud-to-injury pathway, Horn could proceed with his RICO claim despite the CSA's general bar on claims "by reason of" controlled substance violations, since his injury flowed from commercial fraud rather than from use or effects of the substance itself. The decision thus turns on the factual inquiry into what actually caused the harm: deception about what the product contained, not the THC's pharmacological effects.
The Conclusion
**Horn opens a RICO avenue for plaintiffs harmed through fraud involving controlled substances, as long as the fraud rather than the substance itself is the proximate cause of the injury.** Plaintiffs injured by mislabeled or fraudulently marketed CBD and cannabis products now have a viable federal cause of action. The ruling creates a fact-intensive proximate-causation inquiry and is likely to generate significant follow-on litigation in the expanding cannabis and CBD market.
No circuit court data for this case.
Flag an issue
This tracker is maintained by BrynoDC and is free because readers fund it. Support